Efficacy and safety of human dermal fibroblasts cultured in clinical-grade large scale cultured system compared to placebo in treatment of nasolabial folds : A randomized, placebo controlled phase 3, parallel, double blinded clinical trial
Study site: Center for Research and Training in Skin Diseases and Leprosy, Tehran, Iran. After including the eligible patients and receiving their written consent, wrinkle assessment are evaluated by the physician and the patient. 2D imaging and ultrasonographic findings are recorded and the sickness of epiderm and derm plus dermal density will be measured. The patients and outcome assessors are blinded to the interventions.
Participants/Inclusion and exclusion criteria
Inclusion criteria: 30 to 60 years, nasolabial folds, WAS 3to5, length of wrinkle line 12 to 15 cm, written consent to participate/Exclusion criteria: chronic disease,pregnancy , lactation, cancer, HIV, HCV or HBV positive, history of cell therapy, skin interventions in the last 6 months, history of organ transplantation or blood transfusion, immunosuppressive or cytotoxic use in the last 6 months, history of skin mass or benign skin disease, history of anticoagulants use, mesotherapy or skin surgery, injection of permanent fillers, injection of botulinum before the end of efficacy time, HSV history, active infection at the site, heavy diet for weight change, collagen or fibroblast producing diseases, allergy to bovine products, allergy to streptomycin or penicillin, using retinoid drugs during the last 6 months, hypo/hyperthyroidism, history of severe mental problems
Intervention groups
control group:placebo 0.1 ml/cm in each injection
Intervention group: Fibroblast 20millions of cells/ml involume of 0.1ml/cm in each injection
Main outcome variables
remission rate (with at least 2 units change in WAS) based on physician's evaluation and images comparison before and 9 months after the injection
General information
Reason for update
Acronym
IRCT registration information
IRCT registration number:IRCT20100127003200N5
Registration date:2018-06-10, 1397/03/20
Registration timing:registered_while_recruiting
Last update:2018-06-10, 1397/03/20
Update count:1
Registration date
2018-06-10, 1397/03/20
Registrant information
Name
Kazem Heidari
Name of organization / entity
Tehran University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 21 6649 5948
Email address
k_heidari@razi.tums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2018-06-05, 1397/03/15
Expected recruitment end date
2019-06-05, 1398/03/15
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Efficacy and safety of human dermal fibroblasts cultured in clinical-grade large scale cultured system compared to placebo in treatment of nasolabial folds : A randomized, placebo controlled phase 3, parallel, double blinded clinical trial
Public title
Effects of cultured fibroblast on reducing nasolabial folds
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Age between 30-60 years
Having nasolabial folds
Wrinkle Assessment Scale between 3 to 5
Nasolabial fold line length between 12-15 cm
Written consent to participate and willingness to attend in regular treatment / follow up visits
Exclusion criteria:
Having a known chronic disease
pregnancy or plan to be pregnant during the next 5 years
Lactation
history of cancer or chemotherapy
Having viral disease: HIV, HBV or HCV
History of cell therapy
History of lipotransfer at the nasolabial region
UV, laser or PRP interventions in the last 6 months
History of organ transplantation or blood transfusion
History of allergy to anesthetic drugs
History of using immunosuppresive or cytotoxic drugs in the last 6 months
History of Skin mass or benign skin diseases
History of anticoagulant use
Mesotherapy or skin surgery
Injection of permanent fillers
Injection of botulinum or fillers before the end of efficacy time
HSV history
Active infection at the injection site
Diabetes
Being under heavy diet for weigh loss or weight gain
Collagen of fibroblast producing diseases like marfan syndrome or epidermolysis bullosa
History of allergy to bovine products
History of allergy to streptomycin or penicillin
Using retinoid drugs during the last 6 months
Uncontrolled hypothyroidism or hyperthyroidism
History of severe mental problems like depression, anxiety disorders or bipolar disorders
Age
From 30 years old to 60 years old
Gender
Both
Phase
3
Groups that have been masked
Participant
Outcome assessor
Sample size
Target sample size:
60
Randomization (investigator's opinion)
Randomized
Randomization description
Randomization list will be generated using online source: https://www.sealedenvelope.com. Block randomization with block size 4 results in generation of 15 blocks. After the randomization list generation, every patient will be assigned a unique identification code.
All the staff conducting the study will be blinded to randomization list. Opaque sealed consecutively numbered envelopes will be used for the allocation concealment process.Each envelope will be opened after assuring eligibility of the participant and giving written signed consent form.
Blinding (investigator's opinion)
Double blinded
Blinding description
patients will receive similar 100 units, gauge 30 syringes in both groups.
Those who conduct the injections are different form those who conduct the examinations and patients' assessments.
The packages of investigational products will be labelled by unique codes.
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of Vice chancellor for research, Tehran University of Medical Sciences
Street address
Qods street
City
Tehran
Province
Tehran
Postal code
1346694133
Approval date
2018-04-18, 1397/01/29
Ethics committee reference number
IR.TUMS.VCR.REC.1397.091
Health conditions studied
1
Description of health condition studied
Nasolabial folds
ICD-10 code
L98.8
ICD-10 code description
Other specified disorders of the skin and subcutaneous tissue
Primary outcomes
1
Description
Remission rate
Timepoint
Before and nine months after injection
Method of measurement
Wrinkle assessment scale
Secondary outcomes
1
Description
Wrinkle Assessment Scale
Timepoint
Before and weeks 20, 32 and 44 after injection
Method of measurement
score 1 to 5 regarding image comparisons before and after injection
2
Description
Subject Self-assessment of wrinkle
Timepoint
Before and weeks 20, 32 and 44 after injection
Method of measurement
Subject Self-assessment Scale of wrinkle: scroe -2 to +2
3
Description
Length, depth and volume of wrinkle
Timepoint
Before and weeks 20, 32 and 44 after injection
Method of measurement
Two dimensional imaging by VisioFace
4
Description
Thickness of epiderm and derm and dermal density
Timepoint
Before and weeks 20, 32 and 44 after injection
Method of measurement
Ultrasonographic findings
5
Description
Adverse events
Timepoint
Every time happens
Method of measurement
From adverse events list
Intervention groups
1
Description
Control group: Placebo injection 0.1 ml/cm in each injection: three injections in 4 consecutive weeks
Category
Placebo
2
Description
Intervention group: Fibroblast injection 20 millions of cells in 0.1 ml/cm in each injection: three injections in 4 consecutive weeks
Category
Treatment - Drugs
Recruitment centers
1
Recruitment center
Name of recruitment center
Center for Research and Training in Skin Diseases and Leprosy (CRTSDL)
Full name of responsible person
Alireza Firooz
Street address
Taleqani Ave. No 415
City
Tehran
Province
Tehran
Postal code
1416613675
Phone
+98 21 8896 8190
Fax
+98 21 8896 3804
Email
firozali@tums.ac.ir
Web page address
http://crtsdl.tums.ac.ir/index.php/en/
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Barkat pharmaceutical group
Full name of responsible person
Nasser Aghdami
Street address
No. 11, 5th Alley, Bucharest Ave., Argentina Sq
City
Tehran
Province
Tehran
Postal code
1111111111
Phone
+98 21 8848 0161
Fax
+98 21 8848 0160
Email
info@bpharmed.com
Web page address
http://www.bpharmed.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Barkat pharmaceutical group
Proportion provided by this source
50
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry
2
Sponsor
Name of organization / entity
Royan Institute
Full name of responsible person
Nasser Aghdami
Street address
Resalat Highway
City
Tehran
Province
Tehran
Postal code
14669887
Phone
+98 21 8856 1575
Fax
+98 21 8856 1575
Email
nasser.aghdami@royaninstitute.org
Web page address
http://www.royaninstitute.org
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Royan Institute
Proportion provided by this source
50
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Other
Person responsible for general inquiries
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Alireza Firooz
Position
Professor
Latest degree
Specialist
Other areas of specialty/work
Dermatology
Street address
No. 415, Taleqni Ave
City
Tehran
Province
Tehran
Postal code
1416613675
Phone
+98 88972220
Fax
Email
FIROZALI@TUMS.AC.IR
Web page address
Person responsible for scientific inquiries
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Alireza Firooz
Position
Professor
Latest degree
Specialist
Other areas of specialty/work
Dermatology
Street address
No. 415, Taleqni Ave
City
Tehran
Province
Tehran
Postal code
1416613675
Phone
+98 21 8897 2220
Fax
Email
FIROZALI@TUMS.AC.IR
Web page address
Person responsible for updating data
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Kazem Heidari
Position
Non faculty member PhD
Latest degree
Ph.D.
Other areas of specialty/work
Epidemiology
Street address
16th Azar street, Tehran University of Medical Sciences
City
Tehran
Province
Tehran
Postal code
1346694133
Phone
+98 21 4415 1015
Fax
+98 21 8896 3546
Email
k_heidari@razi.tums.ac.ir
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available